ArticleJournal of Korean medical science2013
Comparison of the safety of seven iodinated contrast media.
Article in Journal of Korean medical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration.European radiology · 2022Pooled it
- Contrast-Permeated Suture Tape in Orthopedic Practice: Imaging Characteristics and Mechanical Performance.Cureus · 2026Article
- In vitro Effects of Gadoteric Acid and Iobitridol Toxicity and Platelet-Rich Plasma-Mediated Protection in Human Annulus Fibrosus and Nucleus Pulposus Cells.Journal of pain research · 2026Article
- Characterization of Hypersensitivity to Iodinated Contrast Media: Insights from a Six-Year Cohort of 26,465 Procedures.Healthcare (Basel, Switzerland) · 2025Article
- Effects of iopromide contrast agents on kidney iNOS expression and tubular histopathology alterations.Narra J · 2024Article
- Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company's pharmacovigilance database.The British journal of radiology · 2024Article
- Comparative Safety Profiles and Usage Patterns of Iodinated Contrast Media in Medical Imaging.Diagnostics (Basel, Switzerland) · 2024Article
- Deconvolution Analysis of the Non-Ionic Iomeprol, Iobitridol and Iodixanol Contrast Media-Treated Human Whole Blood Thermograms: A Comparative Study.Diagnostics (Basel, Switzerland) · 2023Article
- Contrast Media Adverse Drug Reactions in Highly Polluted Environment.International journal of environmental research and public health · 2022Article
- Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database.Journal of personalized medicine · 2021Article
- Personalized application of three different concentrations of iodinated contrast media in coronary computed tomography angiography.Journal of cellular and molecular medicine · 2020Article
- Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration: A Nested Case-Control Analysis of 133,331 Patients.Investigative radiology · 2020Observational
- Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro.Journal of experimental orthopaedics · 2018Article
- The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity.Journal of Korean medical science · 2015Article
- Article
- Contrast medium administration and image acquisition parameters in renal CT angiography: what radiologists need to know.Diagnostic and interventional radiology (Ankara, Turkey)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to determine the characteristic adverse events (AEs) of iodinated contrast media (IOCM) and to compare the safety profiles of different IOCM. This study used the database of AEs reports submitted by healthcare professionals from 15 Regional Pharmacovigilance Centers between June 24, 2009 and December 31, 2010 in Korea. All reports of IOCM, including iopromide, iohexol, iopamidol, iomeprol, ioversol, iobitridol and iodixanol, were analyzed. Safety profiles were compared between different IOCM at the system organ level using the proportional reporting ratio (PRR) and 95% confidence interval (95% CI). Among a total of 48,261 reports, 6,524 (13.5%) reports were related to the use of IOCM. Iopromide (45.5%), iohexol (16.9%), iopamidol (14.3%) and iomeprol (10.3%) were identified as frequently reported media. 'Platelet, bleeding & clotting disorders' (PRR, 29.6; 95%CI, 1.9-472.6) and 'urinary system disorders' (PRR, 22.3; 95% CI, 17.1-29.1) were more frequently reported for iodixanol than the other IOCM. In conclusion, the frequency of AEs by organ class was significantly different between individual media. These differences among different IOCM should be considered when selecting a medium among various IOCM and when monitoring patients during and after its use to ensure optimum usage and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.